Letter to FDA Opposing Approval of Liraglutide (Victoza) for Cardiovascular Risk Reduction
FDA response letter to Public Citizen on Victoza cardiovascular risk, July 27, 2017.
In a letter to the Food and Drug Administration (FDA), Public Citizen urged the FDA not to approve liraglutide (Victoza) for the additional indication of reducing cardiovascular risk in type 2 diabetes patients because the clinical trial to support such approval failed to show any benefit in the 2,500 U.S. subjects in the trial. The study only showed a significant benefit in non-U.S. subjects.
View Public Citizen’s previous work on liraglutide.